Intensity-modulated radiation therapy: a review with a physics perspective

Cho, Byungchul

doi:10.3857/roj.2018.00122

Cited by 106 publications

(74 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since IMRT was first performed in 2001 in Korea, implementation of IMRT has been partially covered by national health insurance for specific cancer sites (head and neck, brain, prostate, spinal cancers and re-irradiation cases) from 2011, and since July 2015, the coverage has expanded to include almost all cancers [4]. An abrupt increase from 2015, despite some controversy regarding the cost-effectiveness of IMRT, larger skin dose, and risk of radiation-induced secondary cancers, may have been due to the health insurance coverage and recent advancement in therapeutic machines for IMRT [2,3,7]. The current study showed that the three cancers most frequently treated with IMRT in 2011 were head and neck, prostate, and central nervous system cancers, but in 2018, these were breast, lung, and prostate cancers ( Table 1).…”

Section: Discussionmentioning

confidence: 99%

Recent trends in intensity-modulated radiation therapy use in Korea

2019

View full text Add to dashboard Cite

We aimed to analyze the trend in intensity-modulated radiation therapy (IMRT) use in Korea from 2011 to 2018. Materials and Methods: We collected data from the Health and Insurance Review and Assessment Service (HIRA) big data based on the National Health Insurance Service claims and reimbursements records using primary treatment planning codes (HD 041) for IMRT from 2011 to 2018. We analyzed the changing patterns in clinical application to specific tumor sites and regional differences in IMRT utilization. Results: The use of IMRT has exhibited an 18-fold steep rise from 1,921 patients in 2011 to 34,759 in 2018. With regard to IMRT in 2018, 70% of patients (24,248/34,759) were treated in metropolitan areas (Seoul, Incheon, and Gyeonggi Province). IMRT was most commonly used to treat breast, lung, and prostate cancers in 2018. Among these, the use of IMRT for breast cancer shows the most remarkable increase from 2016 when the National Health Insurance began to cover IMRT for all solid tumors. Conclusion: The use of IMRT is steadily increasing to treat cancer and is concentrated in metropolitan areas.

show abstract

Section: Discussionmentioning

confidence: 99%

Recent trends in intensity-modulated radiation therapy use in Korea

2019

View full text Add to dashboard Cite

show abstract

“…Radiation therapy, along with surgery and chemotherapy, plays a critical role as a main treatment approach for cancer patients [1,2]. Furthermore, radiation therapy trends are shifting from traditional three-dimensional conformal radiation therapy (3DCRT) techniques to complex radiation delivery techniques, such as intensitymodulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), and helical tomotherapy (TOMO), all of which deliver more precise and localized dose distributions [3,4]. Because radiation therapy techniques have become more complex and sophisticated, the importance of proper quality control (QC) and quality assurance (QA) for precise patient care has increased [5][6][7], thereby increasing the importance of accurate in vivo and phantom dose measurements.…”

Section: Introductionmentioning

confidence: 99%

Sensitivity of Radio-Photoluminescence Glass Dosimeters to Accumulated Doses

Kim

Sung

Son

et al. 2020

Preprint

View full text Add to dashboard Cite

Background This study investigated the effect of accumulated doses on radio-photoluminescence glass dosimeters (RPLGDs) from measurements involving mega-voltage photons. Methods Forty-five commercially available RPLGDs were irradiated to estimate their dose responses. Photon beams of 6, 10, and 15 MV were irradiated onto the RPLGDs inside a phantom, which were divided into five groups with different doses and energies. Groups 1 and 2 were irradiated at 1, 5, 10, 50, and 100 Gy in a sequential manner; Group 3 was irradiated 10 times with a dose of 10 Gy; and Groups 4 and 5 followed the same method as that of Group 3, but with doses of 50 Gy and 100 Gy, respectively. Results For the annealed Group 1, RPLGD exhibited a linearity response with variance within 5%. For the non-annealed Group 2, readings demonstrated hyperlinearity at 6 MV and 10 MV, and linearity at 15 MV. Following the 100 Gy irradiation, the readings for Group 2 were 118.7 ± 1.9%, 112.2 ± 2.7%, and 101.5 ± 2.3% at 6, 10, and 15 MV, respectively. For Groups 3, 4, and 5, the responsiveness of the RPLGDs gradually decreased as the number of repeated irradiations increased. The percentage readings for the 10th beam irradiation with respect to the readings for the primary beam irradiation were 84.6 ± 1.9%, 87.5 ± 2.4%, and 93.0 ± 3.0% at 6 MV, 10 MV, and 15 MV, respectively. Conclusions The non-annealed RPLGD response to dose was hyperlinear for the 6 MV and 10 MV photon beams but not for the 15 MV photon beam. Additionally, the annealed RPLGD exhibited a fading phenomenon when the measurement was repeated several times and demonstrated a relatively large fading effect at low energies than at high energies.

show abstract

“…Volumetric modulated arc therapy (VMAT) is an IMRT technique that delivers rotational cone beams with simultaneous modulation of multileaf collimator (MLC) leaves and dose rates [3]. Compared with IMRT which uses fixed gantry angles, VMAT provides an extra degree of freedom, and can reduce treat-ment delivery time and monitor units (MUs) while providing equivalent or improved dose distributions [4,5]. However, because of its complexities in treatment planning and treatment delivery systems, VMAT requires a stringent pretreatment verification to check whether the intended doses will be delivered accurately.…”

Section: Introductionmentioning

confidence: 99%

Three-dimensional dose reconstruction-based pretreatment dosimetric verification in volumetric modulated arc therapy for prostate cancer

Jeong

Kang

et al. 2020

Radiat Oncol J

View full text Add to dashboard Cite

We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated arc therapy (VMAT) for prostate cancer. Materials and Methods: Pretreatment verification for 28 VMAT plans for prostate cancer was performed using the COMPASS system with a dolphin detector. The 3D reconstructed dose distribution of the treatment planning system calculation (TC) was compared with that of COMPASS independent calculation (CC) and COMPASS reconstruction from the dolphin detector measurement (CR). Gamma results (gamma failure rate and average gamma value [GFR and γAvg]) and dose-volume histogram (DVH) deviations, 98%, 2% and mean dose-volume difference (DD 98% , DD 2% and DD mean), were evaluated. Gamma analyses were performed with two acceptance criteria, 2%/2 mm and 3%/3 mm. Results: The GFR in 2%/2 mm criteria were less than 8%, and those in 3%/3 mm criteria were less than 1% for all structures in comparisons between TC, CC, and CR. In the comparison between TC and CR, GFR and γAvg in 2%/2 mm criteria were significantly higher than those in 3%/3 mm criteria. The DVH deviations were within 2%, except for DD mean (%) for rectum and bladder. Conclusions: The 3%/3 mm criteria were not strict enough to identify any discrepancies between planned and measured doses, and DVH deviations were less than 2% in most parameters. Therefore, gamma criteria of 2%/2 mm and DVH related parameters could be a useful tool for pretreatment verification for VMAT in prostate cancer.

show abstract

Intensity-modulated radiation therapy: a review with a physics perspective

Cited by 106 publications

References 42 publications

Recent trends in intensity-modulated radiation therapy use in Korea

Recent trends in intensity-modulated radiation therapy use in Korea

Sensitivity of Radio-Photoluminescence Glass Dosimeters to Accumulated Doses

Three-dimensional dose reconstruction-based pretreatment dosimetric verification in volumetric modulated arc therapy for prostate cancer

Contact Info

Product

Resources

About